Polzastobart by Concentra Biosciences for Metastatic Renal Cell Carcinoma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Polzastobart overview

Polzastobart (JTX-8064) is under development for the treatment of cold tumor including naïve platinum resistant ovarian cancer, head and neck squamous cell carcinoma (HNSCC), extrahepatic bile duct cancer, gallbladder cancer, undifferentiated pleomorphic sarcoma (UPS) and liposarcoma (LPS), non-small cell lung cancer (NSCLC), renal cell carcinoma (ccRCC), triple negative breast cancer (TNBC), cutaneous squamous cell carcinoma (cSCC). It acts by targeting LILRB2 (leukocyte immunoglobulin-like receptor subfamily B member 2). The drug candidate is developed based on translational science platform. It is administered through intravenous route.

Concentra Biosciences overview

Concentra Biosciences is a bioscience company that develops novel immunotherapies for the treatment of cancer. The company is headquartered in San Diego, California, the US.

For a complete picture of Polzastobart’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.